Skip to Content

Blinatumomab

In the US, Blinatumomab (blinatumomab systemic) is a member of the drug class miscellaneous antineoplastics and is used to treat Acute Lymphoblastic Leukemia.

US matches:

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L01XC19

CAS registry number (Chemical Abstracts Service)

0853426-35-4

Chemical Formula

C2367-H3577-N649-O772-S19

Molecular Weight

54085

Therapeutic Categories

Cytostatic agent

Antineoplastic agent: Monoclonal antibody

Chemical Name

Immunoglobulin scFv-scFv, anti-[Homo sapiensCD19 (B lymphocyte surface antigen B4, Leu-12)]/anti-[Homo sapiensCD3 epsilon (CD3E, Leu-4)] Mus musculusmonoclonal antibody bispecific single chain;Mus musculusscFv anti-CD19 [V-KAPPA (IGKV3-4-IGKJ1*01) [10.3.9 (WHO)

Foreign Names

  • Blinatumomabum (Latin)
  • Blinatumomab (German)
  • Blinatumomab (French)
  • Blinatumomab (Spanish)

Generic Names

  • Blinatumomab (OS: USAN)
  • MT-103 (IS)
  • UNII-4FR53SIF3A (IS)

Brand Names

  • Blincyto
    Amgen, Germany; Amgen, United Kingdom; Amgen, United States; Amgen Switzerland, Switzerland

International Drug Name Search

Glossary

TermDefinition
ISInofficial Synonym
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Hide